Build status - In Progress

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA)

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA)
Recruiting
18 years - 99 years
All
Phase 3
50 participants needed
1 Location

Brief description of study

Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Liposarcoma,Neoplasms,Sarcoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female Age 18 or older Histologically confirmed DD liposarcoma

Updated on 04 Aug 2024. Study ID: 849622

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center